



BIODIEM LTD  
ABN 20 096 845 993

Level 4,  
100, Albert Road,  
South Melbourne, Victoria, 3205  
Australia

Phone: +61 3 9692 7240  
Web: [www.biodiem.com](http://www.biodiem.com)

## BioDiem Releases Half Year Results

**Melbourne, 16 March 2015:** Australian infectious disease therapy and vaccine development company BioDiem Ltd today announced its financial results for the half year ended 31 December 2014.

The Company's focus for the half year was on the commercial influenza vaccine licensing business, and BDM-I, BioDiem's antimicrobial development program.

### Highlights

- Launch of Nasovac-S™ in India by commercial partner Serum Institute of India (SII). Nasovac-S is SII's seasonal influenza vaccine product based on BioDiem's technology. A major advantage of Nasovac-S is that it is given by nose drop rather than injected. Royalties from sales of Nasovac-S into the private market are expected to flow to BioDiem before the end of financial year 2015. Currently India is experiencing a swine flu outbreak and more than 1700 deaths have been reported to date.
- Progress of Serum Institute of India's application to the World Health Organisation for prequalification of Nasovac-S. Prequalification, when granted, will allow SII to export to other developing countries of the United Nations. BioDiem will gain income from royalties on sales of Nasovac-S in the private sector of these export markets.
- Progress of our Chinese licensee, Changchun BCHT Biotechnology Co.'s (BCHT) application to conduct clinical trials in China. These trials will be used in support of an application for marketing by BCHT of their influenza vaccine based BioDiem's LAIV influenza technology.
- Exploration of new commercial opportunities in developed world markets for the LAIV technology.
- Development of a plan to take antimicrobial, BDM-I, to proof-of-concept stage in nonclinical models to assist discussions with potential partners. The plan includes expanded formulation presentation.
- Continued expenditure control management.

### Key Results Summary

		% change from previous corresponding period	A\$
Revenue from ordinary activities	Up	15.5%	\$120,623
Loss from ordinary activities	Down	16.5%	(475,782)
Net loss for the half year attributable to equity holders	Down	16.5%	(475,782)

## Other Information

No dividends have been declared or are expected to be declared in the remainder of the year.

Commenting on the results, BioDiem's CEO Julie Phillips said: "With the launch the first seasonal influenza vaccine product based on our technology outside of Russia, the Company is in a new position. The royalty flow to BioDiem is expected to strengthen once the product becomes established in current and new markets. Also the recent transactions in the antimicrobial market supports our view of the attractiveness of BDM-I. Our focus for this asset is to complete the path to proof-of-concept and then commercialise through outlicensing."

- ENDS -

## About BioDiem Ltd

BioDiem is an Australian biopharmaceutical company that is focussed on developing and commercialising vaccines and infectious disease therapies. BioDiem's business model is to generate income from partnerships including with other *vaccine* and *infectious disease treatment* companies through existing and new licences to its LAIV vaccine and other technologies. Income comes from licence fees and royalties on sales.

BioDiem's lead technology is the LAIV (Live Attenuated Influenza Virus) vaccine technology used for production of seasonal and pandemic influenza vaccines and is given intranasally. This technology is licensed currently to two commercial partners, in India and China, and is licenced to the World Health Organisation as part of the Global Pandemic Influenza Action Plan to Increase Vaccine Supply. Serum Institute of India's Nasovac-S™ is based on BioDiem's technology and is already marketed in India. For additional information, please visit [www.biodiem.com](http://www.biodiem.com)

## Further information

Julie Phillips, Chief Executive Officer

BioDiem Ltd

Phone +61 3 9692 7240

Email [jphillips@biodiem.com](mailto:jphillips@biodiem.com)

Twitter @biodiem